Pre-order Enquiry
Request Free Sample
Global CD47 (IAP) Market Growth (Status and Outlook) 2023-2029
SKU ID : LPI-22402528 | Publishing Date : 24-Jan-2023 | No. of pages : 113
Request Sample
Request Customization
Check Discounts
Researcher's newest research report, the “CD47 (IAP) Industry Forecast” looks at past sales and reviews total world CD47 (IAP) sales in 2022, providing a comprehensive analysis by region and market sector of projected CD47 (IAP) sales for 2023 through 2029. With CD47 (IAP) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CD47 (IAP) industry.
This Insight Report provides a comprehensive analysis of the global CD47 (IAP) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CD47 (IAP) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CD47 (IAP) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CD47 (IAP) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CD47 (IAP).
The global CD47 (IAP) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for CD47 (IAP) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for CD47 (IAP) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for CD47 (IAP) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key CD47 (IAP) players cover Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, ImmuneOncia Therapeutics, I-MAB, Sorrento Therapeutics, Zai Lab and ImmuneOnco, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of CD47 (IAP) market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
CD47 Monoclonal Antibody
CD47 Double Antibody
CD47 Fusion Protein
Segmentation by application
Solid Tumor
Lymphoma
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Gilead
Innovent Biologics
Akeso, Inc
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
Sorrento Therapeutics
Zai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
ALX Oncology
Surface Oncology
TG Therapeutics
EpicentRx
This Insight Report provides a comprehensive analysis of the global CD47 (IAP) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CD47 (IAP) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CD47 (IAP) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CD47 (IAP) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CD47 (IAP).
The global CD47 (IAP) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for CD47 (IAP) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for CD47 (IAP) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for CD47 (IAP) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key CD47 (IAP) players cover Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, ImmuneOncia Therapeutics, I-MAB, Sorrento Therapeutics, Zai Lab and ImmuneOnco, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of CD47 (IAP) market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
CD47 Monoclonal Antibody
CD47 Double Antibody
CD47 Fusion Protein
Segmentation by application
Solid Tumor
Lymphoma
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Gilead
Innovent Biologics
Akeso, Inc
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
Sorrento Therapeutics
Zai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
ALX Oncology
Surface Oncology
TG Therapeutics
EpicentRx
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
